Evidence map›Paper›PMID 41494658›Full record

ArticleAmerican journal of physiology. Cell physiology2026

GPR39 activation inhibits AQP2 trafficking and alters cytoskeletal organization.

Mackenzie K Kui, Jessica J Zhang, Ibrahim A Ahmed, Shishir Kumar Patel, Tara Fallah Rastegar, Hamid Rabb, Jennifer L Pluznick

Abstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Novel Roles of GPCRs in the Renal Collecting Duct.Physiology (Bethesda, Md.) · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mackenzie K KuiDepartment of Physiology, Pharmacology, and Therapeutics, Johns Hopkins, Baltimore, Maryland, United States.
Jessica J ZhangDepartment of Physiology, Pharmacology, and Therapeutics, Johns Hopkins, Baltimore, Maryland, United States.
Ibrahim A AhmedDepartment of Physiology, Pharmacology, and Therapeutics, Johns Hopkins, Baltimore, Maryland, United States.
Shishir Kumar PatelDepartment of Medicine and Surgery, Johns Hopkins, Baltimore, Maryland, United States.ORCID 0000-0002-2867-2293
Tara Fallah RastegarDepartment of Medicine and Surgery, Johns Hopkins, Baltimore, Maryland, United States.ORCID 0009-0000-8446-9225
Hamid RabbDepartment of Medicine and Surgery, Johns Hopkins, Baltimore, Maryland, United States.ORCID 0000-0002-4761-1103
Jennifer L PluznickDepartment of Physiology, Pharmacology, and Therapeutics, Johns Hopkins, Baltimore, Maryland, United States.ORCID 0000-0003-3621-2665

Funding

MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007534 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Nadia N Hansel, Larissa A. Shimoda · 1985 to 2026
$28.3M
Uncovering the Role of GPR39 in the kidneyF31DK137460 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI KUI, MACKENZIE · 2024 to 2025
$89k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) T32HL007534HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) F31DK137460NHLBI NIH HHS T32 HL007534NIDDK NIH HHS F31 DK137460
6 · The paper itself

Abstract

G protein-coupled receptor 39 (GPR39) is an orphan receptor that is highly expressed in renal collecting duct principal cells. GPR39 activation in vivo leads to reduced urinary concentration capacity. In this study, we used mpkCCD cells, a model of principal cells in the collecting duct, to examine the cell biological effects of GPR39 activation. Pharmacological activation of GPR39 with the synthetic agonist cpd1324 impaired vasopressin-mediated aquaporin-2 (AQP2) apical trafficking and reduced total AQP2 expression following long-term treatment, consistent with its known in vivo role. These effects were absent in GPR39 knockout cells. In addition, GPR39 activation altered apical membrane morphology, disrupted the tight junction network, and reduced cortical F-actin expression, suggesting a shift toward a dedifferentiated phenotype. GPR39 activation also increased glycolytic ATP production while reducing mitochondrial ATP output without affecting proliferation. RNA-Seq analysis of acutely treated mpkCCD cells revealed upregulation of inflammatory and dedifferentiation-associated gene programs, including cytokines. These findings indicate that the role of GPR39 in principal cells goes beyond AQP2 regulation and imply that GPR39 functions as a negative regulator of epithelial differentiation, perhaps acting to coordinate metabolic and inflammatory responses to stress.

Indexed as

Aquaporin 2CytoskeletonKidney Tubules, CollectingReceptors, G-Protein-CoupledAnimalsCell LineMiceMice, KnockoutProtein TransportTight JunctionsAqp2 protein, mouseAquaporin 2GPR39 protein, mouseReceptors, G-Protein-Coupledaquaporin-2collecting ductcytoskeletonGPCRkidney

Identifiers

PMID41494658
PMCPMC12863663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.